Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Postmenopause: early-phase trial registry

3 of 9 indexed Postmenopause trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

9 US clinical trials · 3 currently recruiting · #1,916 of 28,707 conditions by registered trial count

Postmenopause: 9 US clinical trials tracked, 3 recruiting.

Postmenopause is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is National Center for Complementary and Integrative Health (NCCIH), running 2 of these trials.

Enrollment posture brief

Registry condition postmenopause

OPEN 3 | RECR 33% | LATE 1 | EARLY 3 | RANK #1916 | SPON 2

Volume-matched condition peers

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Postmenopause (this)33%Acute Otitis Media22.2%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near Postmenopause

Postmenopause lists 3 open slots (33% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Postmenopause on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Postmenopause is recruiting below its size-band peers.

    3 of 9 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Postmenopause research.

    National Center for Complementary and Integrative Health (NCCIH) accounts for 2 of 9 trials (22.2%). 8 distinct sponsors appear on at least one study for this condition label.

  3. Most Postmenopause trials plan to enrol fewer than 100 people.

    Median target enrolment is 96 among the 8 trials that report a genuine target (sentinel values excluded). 5 of those (62.5%) plan for fewer than 100 participants.

  4. Postmenopause research is mostly interventional.

    9 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 23Phase 31

Phase Distribution

PhaseTrial count
Phase 2 3
Phase 3 1

Top Sponsors

National Center for Complementary and Integrative Health (NCCIH) 2 trials
National Center for Research Resources (NCRR) 1 trials
Nutrition 21 1 trials
Bayer 1 trials
Buck Institute for Research on Aging 1 trials
Emory University 1 trials
National Heart, Lung, and Blood Institute (NHLBI) 1 trials
University of California, San Diego 1 trials

Named interventions

Most-linked intervention names on Postmenopause records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

MyMenoPlan Other
1 trials
Black Cohosh Drug
1 trials
0.5mg NETA / 1.0mg E2 (Activella) Drug
1 trials
0.25mg DRSP / 0.5mg E2 (BAY86-4891) Drug
1 trials
Estrogen therapy Drug
1 trials
Isoflavones Drug
1 trials
Estrogen Drug
1 trials
Amylopectin-chromium blend Dietary supplement
1 trials

US sites by state

Facility locations filed on Postmenopause trials. A trial with sites in several states counts in each.

Ohio 3 trials
California 3 trials
Texas 2 trials
Washington 1 trials
Virginia 1 trials
South Carolina 1 trials
Pennsylvania 1 trials
New York 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Postmenopause page

9 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Postmenopause condition card totals 9 registered trials; most-linked intervention MyMenoPlan; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.